Press Release: Novartis ianalumab first drug to -2-

Novartis

106.98 CHF 0.18%

• Charts
• News
• Analysen

Kaufen Verkaufen

Reimagine medicine with us: Visit us at https://www.novartis.com/ https://www.novartis.com and connect with us on https://www.linkedin.com/company/novartis/ LinkedIn, https://www.facebook.com/novartis/ Facebook, https://twitter.com/Novartis X/Twitter and https://instagram.com/novartis?igshid=MzRlODBiNWFlZA==__;!!N3hqHg43uw!pjp8z253J5NjaOYrW65UbAAlHeHRdQ-w0m4ezZxEQEl0ptafXN2M99VRIk39pf49PAc8NbK93Pxp3uaSBQkAf8oEnzWXG8Sk$ Instagram.

References

1. Thomas GB, Xavier M, Stephanie F et al. Ianalumab demonstrates

significant reduction in disease activity in patients with Sjögren's

Disease: Efficacy and safety results from two global Phase 3, randomized,

placebo-controlled double-blind studies (NEPTUNUS-1 and NEPTUNUS-2).

Presented at the American College of Rheumatology (ACR) Congress; October

24-29, 2025; Chicago, Illinois

2. National Academies of Sciences, Engineering, and Medicine; Health and

Medicine Division; Board on Health Care Services; Committee on Selected

Immune Disorders and Disability. Sjögren's Disease/Syndrome. [Last

accessed: October 2025] https://www.ncbi.nlm.nih.gov/books/NBK584486/

3. Dorner T et al, Safety and Efficacy of ianalumab in patients with

Sjögren's disease: 52-week results from a randomized,

placebo-controlled, Phase 2b dose-ranging study, Arthritis and

Rheumatology 2025, 77(5):560-570

4. Lee AY, Qi Z, Jackson KJ, et al. Self-reactive B cells are increased in

all major stages of peripheral development in Sjögren's disease.

Immunology & Cell Biology 2025; 103: 401-410.

5. Both T, Dalm VA, van Hagen PM, et al. Reviewing primary Sjögren's

syndrome: beyond the dryness - From pathophysiology to diagnosis and

treatment. Int J Med Sci 2017; 14: 191-200.

6. Cornec D, Devauchelle-Pensec V, Tobón GJ, et al. B cells in

Sjögren's syndrome: from pathophysiology to diagnosis and treatment.

J Autoimmun 2012; 39: 161-167.

7. ClinicalTrials.gov NCT05350072

https://clinicaltrials.gov/study/NCT05350072 [Last accessed: October

2025]

8. ClinicalTrials.gov NCT0539214

https://clinicaltrials.gov/study/NCT05349214 [Last accessed: October

2025]

9. ClinicalTrials.gov NCT05985915

https://clinicaltrials.gov/study/NCT05985915 [Last accessed: October

2025]

10. ClinicalTrials.gov NCT05653219

https://clinicaltrials.gov/study/NCT05653219?intr=ianalumab&aggFilters=phase:3&rank=9

[Last accessed: October 2025]

11. ClinicalTrials.gov NCT05639114

https://www.clinicaltrials.gov/study/NCT05639114 [Last accessed: October

2025]

12. ClinicalTrials.gov NCT05126277

https://clinicaltrials.gov/study/NCT05126277 [Last accessed: October

2025]

13. ClinicalTrials.gov NCT05648968

https://clinicaltrials.gov/study/NCT05648968 [Last accessed: October

2025]

14. ClinicalTrials.gov NTC06470048

https://clinicaltrials.gov/study/NCT06470048 [Last accessed: October

2025]

15. Novartis to strengthen oncology pipeline with agreement to acquire

MorphoSys [AG Press release]. [Press release]. Available at: Novartis to

strengthen oncology pipeline with agreement to acquire MorphoSys AG for

EUR 68 per share or an aggregate of EUR 2.7bn in cash | Novartis

https://www.novartis.com/news/media-releases/novartis-strengthen-oncology-pipeline-agreement-acquire-morphosys-ag-eur-68-share-or-aggregate-eur-27bn-cash

[Last accessed: October 2025]

16. Negrini S et al, Sjögren's syndrome: a systemic autoimmune disease,

Clin Exp Med. 2022; 22(1): 9--25

17. Maleki Fischbach-M, et al, Manifestations and management of

Sjögren's disease, Arthritis Res Ther, 2024; 26(1):43

18. Mariette, Primary Sjögren's symptoms, New England Journal of

Medicine, 2018, 378;10

19. Kerry Gairy et al, Burden of illness among subgroups of px with primary

SjD and systemic involvement, Rheumatology 2021, Volume 60, Issue 4,

April 2021, Pages 1871--1881

20. Conrad N, et al, Incidence, prevalence, and co-occurrence of autoimmune

disorders over time and by age, sex, and socioeconomic status: a

population-based cohort study of 22 millions individuals in the UK,

Lancet. 2023;401(10391):1878-1890;

21. Narváez J et al, Prevalence of Sjögren's syndrome in the

general adult population in Spain: estimating the proportion of

undiagnosed cases, Sci Rep. 2020;10(1):10627

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

(END) Dow Jones Newswires

October 29, 2025 10:30 ET (14:30 GMT)